Crohns Disease - Biotech, Pharma and Life Science Channel
Crohns Disease is a chronic inflammatory disease, affecting the whole of the alimentary tract from mouth to anus, and all layers of the gut wall. The most commonly affected sites are the terminal ileum, and the large intestine. It frequently affects the anus and is characteristically patchy in distribution.
Crohns disease is characteristically chronic with periods of remission and relapses, a wide range of symptoms, and extra-intestinal complications. There is a strong tendency for it to recur after surgery.
Despite extensive and continuing research the cause of Crohn’s Disease is still unknown, but predisposing factors could be infection, immunological factors, dietary factors, psychological factors (such as emotional stress), smoking and genetics.
These factors offer considerable potential for new research and treatment. Future work will focus on manipulation of bacteria in the bowel and the dissection of the immune response in order to provide agents, which block its development.
Already monoclonal antibodies exist against TNF-a and a-integrins. Drugs are being developed against NF- B, which initiates much of the inflammatory process. Others such as CDP-571, Etanercept, Thalidomide, Tacrolimus and Mycophenolate mofetil are being evaluated; new compounds continue to emerge.
Source; Adapted from http://www.crohns.org.uk/
Add the Crohns Disease News Channel to your RSS reader;
Follow the Crohns Twitter Feed;
VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 28, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to announce the appointment of Mr. John K. Bel...
ATLANTA, Nov. 30, 2012 /PRNewswire/ -- In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease an...
SPRING HOUSE, Pa., Oct. 17, 2012 /PRNewswire/ -- Findings from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial evaluating the efficacy and safety of STELARA® (us...
Cornerstones Health Inc., a nonprofit organization working to improve communication between patients with inflammatory bowel diseases (IBD) and physicians who treat IBD, in...
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women fo...
Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.
The purpose of this study is to evaluate the blood levels of Metronidazole after application to the peri anal area after a single dose and 6 or 7 days application.
A medical research study in adult patients who have moderate to severe Crohns disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO12...
This study is looking at the advantage of establishing surgical drainage for Crohn's fistulas and abscesses prior to starting medical therapy.
The investigators will prospectively recruit 26 children with moderate - severe active Crohn disease (PCDAI >30). Results will be compared to 26 patients in sustained remission (PCDAI
To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to cur...
A diagnosis of idiopathic inflammatory bowel disease requires synthesis of clinical, radiographic, endoscopic, surgical, and histologic data. While most cases of inflammatory bowel disease can be spec...